While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...
2don MSN
Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...
By pausing DMARDs, you may be ‘starting the cascade of getting the patient into trouble by interrupting therapy that’s ...
Delays in diagnosing and treating psoriatic arthritis – a common inflammatory disorder affecting 112 in every 100,000 adults – are causing irreparable ...
Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and joint pain, but excess fatigue is also a symptom for at least 50% of people with PsA. Fatigue from PsA might be mild ...
Psoriatic arthritis (PsA) is an immune-mediated condition, and people with PsA may be at a higher risk of developing many neurological conditions. Psoriatic arthritis (PsA) is an immune-mediated ...
A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to ...
The following is a summary of “Advancement and independent validation of a deep learning-based tool for automated scoring of ...
Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.
Psoriatic arthritis can affect any joint in the body, including the elbow. When joints are affected, symptoms may resemble other types of arthritis. Inflammatory arthritis happens when the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results